Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 2;6(5):e1306619.
doi: 10.1080/2162402X.2017.1306619. eCollection 2017.

Cellular immunotherapies for cancer

Pedro Berraondo  1   2   3 , Sara Labiano  1   2 , Luna Minute  1   2 , Iñaki Etxeberria  1   2 , Marcos Vasquez  1   2 , Alvaro Sanchez-Arraez  1   2 , Alvaro Teijeira  1   2   3 , Ignacio Melero  1   2   3   4
Affiliations
Review

Cellular immunotherapies for cancer

Pedro Berraondo et al. Oncoimmunology. .

Abstract

Lessons learned over decades on the use of gene and cell therapies have found clinical applicability in the field of cancer immunotherapy. On December 16th, 2016 a symposium was held in Pamplona (Spain) to analyze and discuss the critical points for the clinical success of adoptive cell transfer strategies in cancer immunotherapy. Cellular immunotherapy is being currently exploited for the development of new cancer vaccines using ex vivo manipulated dendritic cells or to enhance the number of effector cells, transferring reinvigorated NK cells or T cells. In this meeting report, we summarize the main topics covered and provide an overview of the field of cellular immunotherapy.

Keywords: Chimeric antigen receptor; NK cells; Tumor-infiltrating lymphocytes; dendritic cells.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cellular immunotherapy strategies. Cancer immune response starts with the release of tumor-associated antigens and danger signals by dying tumor cells (immunogenic cell death). Dendritic cells capture tumor-associated antigens and mature due to the detection of danger signals by pattern-recognition receptors. Upon migration to the lymph node, dendritic cells are able to trigger the effector antitumor response. Cytotoxic T lymphocytes and NK cells recognize and kill the tumor cells. Adoptive transfer of dendritic cells, T cells or NK cells are being used to boost this process.
See this image and copyright information in PMC

References

    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID: 20525992; https://doi.org/10.1056/NEJMoa1003466 - DOI - PMC - PubMed
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID: 25399552; https://doi.org/10.1056/NEJMoa1412082 - DOI - PubMed
    1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al.. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID: 23724867; https://doi.org/10.1056/NEJMoa1302369 - DOI - PMC - PubMed
    1. Bertrand F, Muller S, Roh KH, Laurent C, Dupre L, Valitutti S. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse. Proc Natl Acad Sci USA 2013; 110:6073-8; PMID: 23536289; https://doi.org/10.1073/pnas.1218640110 - DOI - PMC - PubMed
    1. Vasconcelos Z, Muller S, Guipouy D, Yu W, Christophe C, Gadat S, Valitutti S, Dupré L. Individual human cytotoxic T Lymphocytes exhibit intraclonal heterogeneity during sustained killing. Cell Rep 2015; 11:1474-85; PMID: 26027932; https://doi.org/10.1016/j.celrep.2015.05.002 - DOI - PubMed

Publication types

LinkOut - more resources